2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2015
The Effect of a Whey Protein Supplement on Bone Mass in Older Caucasian Adults
Kerstetter JE, Bihuniak JD, Brindisi J, Sullivan RR, Mangano KM, Larocque S, Kotler BM, Simpson CA, Cusano A, Gaffney-Stomberg E, Kleppinger A, Reynolds J, Dziura J, Kenny AM, Insogna KL. The Effect of a Whey Protein Supplement on Bone Mass in Older Caucasian Adults. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 2214-2222. PMID: 25844619, PMCID: PMC4454800, DOI: 10.1210/jc.2014-3792.Peer-Reviewed Original ResearchConceptsBone mineral densityBone resorptionL-spine bone mineral densitySelf-reported protein intakeDual-energy X-ray absorptiometryTruncal lean massPlacebo-controlled trialGlomerular filtration rateBody mass indexProtein supplementationC-terminal telopeptideX-ray absorptiometryFat-free massWhey protein supplementHigh-protein dietHealthy older adultsOlder Caucasian adultsUrine calciumRenal functionMass indexSkeletal healthUsual dietFiltration rateMineral densityBone mass
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisCharacteristics of patientsC-peptide levelsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
2006
AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders
Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B. AProspective Open Trial of Guanfacine in Children with Pervasive Developmental Disorders. Journal Of Child And Adolescent Psychopharmacology 2006, 16: 589-598. PMID: 17069547, DOI: 10.1089/cap.2006.16.589.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic alpha-AgonistsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildChild Development Disorders, PervasiveChild, PreschoolFemaleGuanfacineHumansMaleMethylphenidatePersonality AssessmentPilot ProjectsProspective StudiesTreatment FailureTreatment OutcomeConceptsOpen-label trialAberrant Behavior ChecklistPervasive developmental disorderClinical Global Impression-ImprovementHyperactivity subscaleEfficacy of guanfacinePlacebo-controlled trialCommon adverse effectsWeeks of treatmentTreatment of hyperactivityDevelopmental disordersBlood pressureOpen trialMean ageSleep disturbancesCommon complaintClinical practiceGuanfacineHyperactivityPilot studyAdverse effectsTrialsBehavior ChecklistChildrenMethylphenidate